Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05088356 · ClinicalTrials.gov registry record · Phase 1
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
A Phase 1 study of Myelodysplastic Syndromes and Acute Leukemia, sponsored by Stanford University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT05088356 is a Phase 1 study of Myelodysplastic Syndromes and Acute Leukemia that is actively recruiting participants, run by Stanford University. The registered enrollment target is 60 participants, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05088356, a Phase 1 study of Myelodysplastic Syndromes and Acute Leukemia, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
Reduced intensity conditioning (RIC) has emerged and been increasingly adopted as a modality to allow preparative conditioning pre transplant to be tolerated by older adults or those patients that are otherwise unfit for myeloablative conditioning. In this study, we aim to use RIC followed by matched related/unrelated donor, 7/8 matched related/unrelated donor, or haploidentical donor peripheral blood stem cell transplantation. Standard strategies to control the alloreactivity following HCT utilize immunosuppressive or cytotoxic medications. In this study, we explore donor graft engineering to enrich for immmunoregulatory populations to facilitate post transplantation immune reconstitution while minimizing graft versus host disease (GVHD) with post-transplant immunosuppressive agents.
Conditions Studied
Interventions
- DRUG Fludarabine
- DRUG Melphalan
- DRUG Tacrolimus
- DRUG Purified regulatory T-cells (Treg) plus CD34+ HSPC
- DEVICE CliniMACS CD34 Reagent System
Study Locations (1)
California
- Stanford University - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2021-09-07 |
| Est. Completion | 2027-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05088356
The ClinicalTrials.gov registry entry for NCT05088356 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (79% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Myelodysplastic Syndromes appearing as the primary indexed condition, and to 5 interventions - of which Fludarabine is the first listed.
NCT05088356 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05088356 about?
NCT05088356 is a clinical study titled "Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft". Reduced intensity conditioning (RIC) has emerged and been increasingly adopted as a modality to allow preparative conditioning pre transplant to be tolerated by older adults or those patients that are otherwise unfit for myeloablative conditioning. In this study, we aim to use RIC followed by matche...
What is the current status of trial NCT05088356?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2021-09-07. Estimated completion is 2027-11.
What conditions does trial NCT05088356 study?
This clinical trial studies the following conditions: Myelodysplastic Syndromes, Acute Leukemia, Chronic Myelogenous Leukemia, Myeloproliferative Disorders, Allogeneic Hematopoietic Cell Transplantation (HCT).
What interventions are being tested in trial NCT05088356?
The interventions under investigation include: Fludarabine (DRUG), Melphalan (DRUG), Tacrolimus (DRUG), Purified regulatory T-cells (Treg) plus CD34+ HSPC (DRUG), CliniMACS CD34 Reagent System (DEVICE).
Who is sponsoring clinical trial NCT05088356?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05088356 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelodysplastic Syndromes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
RECRUITING · Phase 1
-
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
RECRUITING · Phase 1
-
A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation
RECRUITING · Phase 1
-
HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML
RECRUITING · Phase 1
-
A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes
RECRUITING · Phase 1
-
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.